eligibility_summary
Include: Adults 30–75 with BCMA+ relapsed/refractory disease, high tumor burden pre‑transplant for debulking, post‑transplant relapse with failed DLI, persistent MRD+, survival >12 wks, negative pregnancy test/contraception, relapse after any prior therapy, consent. Exclude: CNS disease/epilepsy, QT prolongation/severe heart disease, pregnancy/breastfeeding, uncontrolled infection (HBV/HCV/HIV), prior gene therapy, poor T‑cell expansion, renal/hepatic dysfunction, other risks per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 1, single-arm study in relapsed/refractory multiple myeloma testing autologous hematopoietic stem cell transplantation (AHSCT) combined with BCMA CAR-T cells. Interventions: BCMA-directed CAR-T cell therapy (autologous, gene‑modified T‑cell immunotherapy) plus AHSCT (procedure following high-dose chemotherapy to reconstitute marrow). Mechanisms: CAR-T cells recognize B‑cell maturation antigen (BCMA/TNFRSF17) on malignant plasma cells, activating T‑cell cytotoxicity and cytokine release to kill tumor, AHSCT aims to deepen response and restore hematopoiesis after cytotoxic conditioning. Targets: BCMA-expressing plasma cells, T‑cell activation/cytotoxic pathways, hematopoietic stem cell compartment for marrow reconstitution. Outcomes: CR, ORR, relapse, safety.